Aclaris Therapeutics Short Interest Ratio and Short Volume

-0.13 (-0.45 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $28.96
50-Day Range
MA: $23.97
52-Week Range
Now: $28.96
Volume416,129 shs
Average Volume2.81 million shs
Market Capitalization$1.50 billion
P/E RatioN/A
Dividend YieldN/A

Short Interest

Aclaris Therapeutics (NASDAQ:ACRS) Short Interest Data

Current Short Volume644,000 shares
Previous Short Volume759,000 shares
Change Vs. Previous Month:-15.15%
Dollar Volume Sold Short$14.82 million
Short Interest Ratio / Days to Cover0.2
Last Record DateMarch, 15 2021
Outstanding Shares41,270,000 shares
Float Size36,270,000 shares
Short Percent of Float1.78%
Today's Trading Volume416,129 shares
Average Trading Volume2,806,499 shares
Today's Volume Vs. Average-85.17%

Short Interest Over Time

Aclaris Therapeutics (NASDAQ:ACRS) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/15/2021644,000 shares $14.82 million -15.2%1.8%0.2 $23.02
2/26/2021759,000 shares $17.32 million -47.7%1.9%0.3 $22.82
2/12/20211,450,000 shares $32.31 million +52.7%3.9%0.5 $22.28
1/29/2021949,600 shares $21.77 million +69.1%2.7%0.3 $22.93
1/15/2021561,500 shares $10.96 million -18.4%1.6%0.2 $19.52
12/31/2020484,000 shares $3.06 million -12.8%1.6%0.7 $6.32
12/15/2020484,000 shares $3.17 million -12.8%1.6%0.7 $6.55
11/30/2020555,300 shares $3.07 million -9.4%1.8%1.4 $5.52
11/15/2020613,200 shares $2.05 million -10.1%2.0%1.5 $3.34
10/30/2020682,300 shares $2.48 million +5.7%2.2%1.6 $3.64
10/15/2020645,400 shares $2.59 million -6.7%2.0%1.3 $4.02
9/30/2020691,500 shares $2.87 million +17.0%2.1%1.1 $4.15
9/15/2020591,100 shares $1.45 million -12.0%1.8%0.9 $2.46
8/31/2020671,700 shares $1.46 million -19.7%2.1%0.8 $2.18
8/14/2020836,700 shares $1.95 million -12.3%2.6%1 $2.33
7/31/2020953,500 shares $2.26 million -23.1%3.0%1.2 $2.37
7/15/20201,240,000 shares $2.67 million -9.5%4.0%1.8 $2.15
6/30/20201,370,000 shares $2.95 million -21.7%4.4%2.6 $2.15
6/15/20201,750,000 shares $2.80 million +0.6%5.6%4.1 $1.60
5/29/20201,740,000 shares $2.73 million -11.2%5.5%6.1 $1.57
5/15/20201,960,000 shares $2.76 million -7.1%6.2%6.2 $1.41
4/30/20202,110,000 shares $2.83 million -12.8%6.6%5.2 $1.34
4/15/20202,420,000 shares $3.48 million -37.6%7.7%4.9 $1.44
3/31/20203,880,000 shares $4.19 million -25.0%12.5%5.7 $1.08
3/13/20205,176,300 shares $5.95 million +21.2%16.6%15 $1.15

Aclaris Therapeutics (NASDAQ:ACRS) Short Interest FAQ

speech bubbles
speech bubbles

What is Aclaris Therapeutics' current short interest?

Short interest is the volume of Aclaris Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 644,000 shares of ACRS short. 1.78% of Aclaris Therapeutics' shares are currently sold short. View details.

What is a good short interest percentage for Aclaris Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.78% of Aclaris Therapeutics' floating shares are currently sold short.

Is Aclaris Therapeutics' short interest increasing or decreasing?

Aclaris Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 644,000 shares, a drop of 15.2% from the previous total of 759,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Aclaris Therapeutics' float size?

Aclaris Therapeutics currently has issued a total of 51,804,000 shares. Some of Aclaris Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aclaris Therapeutics currently has a public float of 36,270,000 shares.

How does Aclaris Therapeutics' short interest compare to its competitors?

1.78% of Aclaris Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Aclaris Therapeutics: Ionis Pharmaceuticals, Inc. (6.40%), Sarepta Therapeutics, Inc. (0.00%), Allakos Inc. (9.33%), Blueprint Medicines Co. (0.00%), Perrigo Company plc (3.69%), Schrödinger, Inc. (6.64%), Galapagos NV (0.00%), Atea Pharmaceuticals, Inc. (4.89%), Sage Therapeutics, Inc. (0.00%), and Biohaven Pharmaceutical Holding Company Ltd. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon plc ($5.64 billion), Analog Devices, Inc. ($5.59 billion), Charter Communications, Inc. ($5.47 billion), ViacomCBS Inc. ($4.95 billion), Baidu, Inc. ($3.51 billion), Snap Inc. ($3.18 billion), Airbnb, Inc. ($2.38 billion), The Kroger Co. ($2.28 billion), Expedia Group, Inc. ($2.24 billion), and Bilibili Inc. ($2.06 billion). View all of the most shorted stocks.

What does it mean to sell short Aclaris Therapeutics stock?

Short selling ACRS is an investing strategy that aims to generate trading profit from Aclaris Therapeutics as its price is falling. Aclaris Therapeutics' stock is trading down $0.13 today. To short Aclaris Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Aclaris Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Aclaris Therapeutics?

A short squeeze for Aclaris Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ACRS, which in turn drives the price of the stock up even further.

How often is Aclaris Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ACRS, twice per month. The most recent reporting period available is March, 15 2021.

This page was last updated on 4/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.